Luitpold buys PharmaForce for generic injectables

By Nick Taylor

- Last updated on GMT

Related tags: Pharmaceutical drug, Pharmacology

Daiichi-Sankyo subsidiary Luitpold Pharmaceuticals has acquired PharmaForce, giving it a 40,000 sq ft cGMP compliant sterile manufacturing facility and a 20,000 sq ft API production plant.

The deal is part of Luitpold’s efforts to diversify its product portfolio and generate growth. In particular Luitpold has identified the generic injectable market as a growth opportunity.

By acquiring PharmaForce it has strengthened its position in the market for difficult to manufacture sterile drugs and generic injectables and bolstered R&D and production capacity.

In addition to the current good manufacturing practice (cGMP) compliant facility and the active pharmaceutical ingredient (API) production plant the deal also includes a 20,000 sq ft R&D site.

Acquiring the R&D site immediately boosts Luitpold’s infrastructure, expertise and pipeline, providing it with a platform to become the sole source or first-to-market for generic injectable products.

The acquisition has been cleared by the US Federal Trade Commission (FTC) and Luitpold has purchased 100 per cent of PharmaForce’s stock. Following the deal Columbus, Ohio, US-based PharmaForce’s products will be marketed by Luitpold’s subsidiary, American Reagent.

Daiichi targets Africa

Daiichi-Sankyo, which owns Luitpold, is planning to use Ranbaxy Laboratories’, also owned the Japan-based pharma, presence in Africa to launch a product in six countries on the continent.

In December 2009 Daiichi outlined its intention for Ranbaxy to launch Olmesartan Medoxomil, originally discovered by the Japanese pharma, in Kenya, Mozambique, Nigeria, Tanzania, Uganda and Zambia.

This will use Ranbaxy’s established presence in Africa and is a continuation of Daiichi’s efforts to benefit from the companies’ respective strengths following its $4.5bn (€3.1bn) acquisition of the Indian generics firm.

In April 2009 Ranbaxy launched Olmesartan Medoxomil in India under the name Olvance. This was followed in August by the Indian launch of a fixed-dose combination of Olmesartan Medoxomil with Amlodipine Besylate.

Related news

Related products

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers